Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors

Program Goals

Idelalisib Discontinuations: Pooled Data From Phase 3 Clinical Trials[a]

Ibrutinib Discontinuations: Single-Center Pooled Data From 4 Clinical Trials

Assessing Disease Progression

BCR Signaling Inhibitors: Key AEs in Phase 3 Clinical Trials

Discontinuing BCR Signaling Inhibitors: Multicenter Clinical Practice Experience

Case #1: Discontinuation of Ibrutinib Due to AEs

Considerations in Managing Patients With Ibrutinib-Associated AEs

Factors Associated With Ibrutinib Failure: Single-Center Pooled Data From 4 Clinical Trials

Case #1: Discontinuation of Ibrutinib Due to AEs - Switch BCR Signaling Inhibitor

Considerations in Managing Patients With Idelalisib-Associated AEs

Case #2: Discontinuation of Idelalisib + Rituximab Due to Progression

Case #2: Discontinuation of Idelalisib + Rituximab Due to Progression (cont)

Factors Associated With Idelalisib Failure: Subgroup Analysis of Phase 3 Data

Outcomes in Patients Who Progress With Richter's Transformation on Idelalisib: Pooled Data From Phase 3 Clinical Trials

Outcomes in Patients Who Discontinue Idelalisib: Pooled Data From Phase 3 Clinical Trials

Treatment Options After Discontinuing a BCR Signaling Inhibitor

Survival After Switching BCR Signaling Inhibitors: Multicenter Clinical Practice Experience

Venetoclax After Idelalisib or Ibrutinib: Ongoing Phase 2 Trial

Investigational Approaches With Venetoclax

BTK Inhibitors in Development

Role of Allogeneic Stem Cell Transplantation

Potential Role of CAR T-Cell Therapy

Case #1: Discontinuation of Idelalisib Due to Disease Progression - Final Follow-Up

Venetoclax + Rituximab in Patients With R/R CLL: Phase 1b Long-Term Data

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)